148 related articles for article (PubMed ID: 38394504)
1. An unusual evolution of thyroid function after therapeutic plasma exchange in Graves' disease with cholestatic jaundice: A case report.
Jin Y; Feng X; Ni H
Medicine (Baltimore); 2024 Feb; 103(8):e37074. PubMed ID: 38394504
[TBL] [Abstract][Full Text] [Related]
2. Role of plasma exchange in autoimmune hyperthyroidism complicated by severe tiamazol-induced cholestatic jaundice.
Miljić D; Stojanović M; Ješić R; Bogadnović G; Popović V
Transfus Apher Sci; 2013 Oct; 49(2):354-6. PubMed ID: 23756266
[TBL] [Abstract][Full Text] [Related]
3. Steroids for the treatment of methimazole-induced severe cholestatic jaundice in a 74-year-old woman with type 2 diabetes.
Zhang M; Zhou H; He R; Di F; Yang L; Yang T
Endocrine; 2010 Apr; 37(2):241-3. PubMed ID: 20960257
[TBL] [Abstract][Full Text] [Related]
4. Methimazole-induced cholestatic jaundice in an elderly hyperthyroid patient.
Ramos-Bonner LS; Goldberg TH; Moyer S; Anastasopoulou C
Am J Geriatr Pharmacother; 2007 Sep; 5(3):236-40. PubMed ID: 17996663
[TBL] [Abstract][Full Text] [Related]
5. Rash and cholestatic liver injury caused by methimazole in a woman with Turner syndrome and Graves's disease: a case report and literature review.
Zeng J; Luo F; Lin Z; Chen Y; Wang X; Song Y
BMC Endocr Disord; 2021 Sep; 21(1):179. PubMed ID: 34479513
[TBL] [Abstract][Full Text] [Related]
6. [Methimazole-induced cholestatic jaundice in a hyperthyroid patient].
López-P Rdel P; Forero JD; Sierra F
Acta Gastroenterol Latinoam; 2014 Mar; 44(1):52-8. PubMed ID: 24847631
[TBL] [Abstract][Full Text] [Related]
7. Concomitant methimazole-induced agranulocytosis and cholestatic jaundice in a young woman.
Alcorn C; Subarajan P; Anderson J
BMJ Case Rep; 2022 Aug; 15(8):. PubMed ID: 36007972
[TBL] [Abstract][Full Text] [Related]
8. Case report: Severe cholestatic jaundice associated with hyperthyroidism treated with methimazole.
Liu X; Xu B; Zeng Y; Chen P; Wang Y
Medicine (Baltimore); 2023 Nov; 102(45):e35972. PubMed ID: 37960740
[TBL] [Abstract][Full Text] [Related]
9. The Long-Term Outcome of Treatment for Graves' Hyperthyroidism.
Sjölin G; Holmberg M; Törring O; Byström K; Khamisi S; de Laval D; Abraham-Nordling M; Calissendorff J; Lantz M; Hallengren B; Filipsson Nyström H; Wallin G
Thyroid; 2019 Nov; 29(11):1545-1557. PubMed ID: 31482765
[No Abstract] [Full Text] [Related]
10. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
[TBL] [Abstract][Full Text] [Related]
11. Methimazole-induced cholestatic jaundice.
Mikhail NE
South Med J; 2004 Feb; 97(2):178-82. PubMed ID: 14982270
[TBL] [Abstract][Full Text] [Related]
12. Very rare case of Graves' disease with resistance to methimazole: a case report and literature review.
Mori Y; Hiromura M; Terasaki M; Kushima H; Ohara M; Fukui T; Takahashi Y; Yamagishi SI
J Int Med Res; 2021 Mar; 49(3):300060521996192. PubMed ID: 33682498
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study.
Mazza E; Carlini M; Flecchia D; Blatto A; Zuccarini O; Gamba S; Beninati S; Messina M
J Endocrinol Invest; 2008 Oct; 31(10):866-72. PubMed ID: 19092290
[TBL] [Abstract][Full Text] [Related]
14. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease.
Alexander EK; Larsen PR
J Clin Endocrinol Metab; 2002 Mar; 87(3):1073-7. PubMed ID: 11889166
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience of treating Graves' hyperthyroidism complicated with malignancy-The possible role of potassium iodide for avoiding the risk of thionamide-associated neutropenia.
Okamura K; Bandai S; Fujikawa M; Sato K; Kitazono T
Endocr J; 2020 Jul; 67(7):751-758. PubMed ID: 32238669
[TBL] [Abstract][Full Text] [Related]
16. Management of Graves Thyroidal and Extrathyroidal Disease: An Update.
Kahaly GJ
J Clin Endocrinol Metab; 2020 Dec; 105(12):3704-20. PubMed ID: 32929476
[TBL] [Abstract][Full Text] [Related]
17. Apathetic Graves' disease with severe hepatic and renal dysfunction induced by COVID-19 infection: Case report and literature review.
Deng L; Zhang Y; Sun H
Medicine (Baltimore); 2024 Mar; 103(11):e37456. PubMed ID: 38489722
[TBL] [Abstract][Full Text] [Related]
18. Myopathy after rapid correction of hyperthyroidism: A case report and review of literature.
Lu R; Wang H; Hong T; Gao H
Medicine (Baltimore); 2020 Jan; 99(3):e18878. PubMed ID: 32011514
[TBL] [Abstract][Full Text] [Related]
19. Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial.
Leo M; Bartalena L; Rotondo Dottore G; Piantanida E; Premoli P; Ionni I; Di Cera M; Masiello E; Sassi L; Tanda ML; Latrofa F; Vitti P; Marcocci C; Marinò M
J Endocrinol Invest; 2017 Mar; 40(3):281-287. PubMed ID: 27734319
[TBL] [Abstract][Full Text] [Related]
20. Time to Normalization and Sustainable Normal Serum Thyrotropin Concentrations in Patients with Hyperthyroidism: Comparison of Methimazole and Radioactive Iodine Treatments.
Azizi F; Saadat N; Abdi H; Mehran L; Masoumi S; Takyar MA; Amouzegar A
Endocr Pract; 2022 Nov; 28(11):1140-1145. PubMed ID: 35948251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
